Astrana Health

Aging US Population And Medicare Advantage Will Transform Care Delivery

AnalystHighTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

04 May 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$54.00

45.7% undervalued

15 Aug

US$29.33

-39.2%

4.5%

Author's Valuation

US$54.0

45.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Decreased 19%

AnalystHighTarget Fair Value

US$54.0

45.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

17.20%

Healthcare Services revenue growth rate

0.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$160.64m

Earnings '28

21.28x

PE Ratio '28

US$3.42b

Market Cap '28

US$3.42b

Market Cap '28

52.56m

No. shares '28

US$65.04

Share Price '28

US$65.04 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$53.43

Fair Value '25

Aging US Population And Medicare Advantage Will Transform Care Delivery

Shared on07 May 25Fair value Decreased 19%

Shared on07 May 25
Fair value Decreased 19%